Background: Point-of-care lactate devices are used worldwide for intrapartum decision making. Current practice is often based on Lactate Pro (Arkray) but its imminent product discontinuation necessitates determination of an optimal replacement device.
Aims:To evaluate the performance of Lactate Pro and two other point-of-care devices, Lactate Pro 2 (Arkray) and StatStrip (Nova Biomedical), and to derive scalp lactate cut-offs equivalent to the current intervention trigger of >4.8 mmol/L.
Materials and methods: Paired umbilical cord arterial and venous blood sam-ples from 109 births were tested on the three point-of-care products (two devices each), cross-compared with the reference method blood gas analyser.